Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study.

Next Previous
X
Search
Trial Profile

A randomized, double blind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Acronyms RINOMAX

    • Most Recent Events

    • 19 Sep 2022 Primary endpoint ( (Percentage of patients with quantitative MG ascore (QMG) score 4 and a daily Prednisolon dose of 10mg at 16 weeks after administration of study drug/placebo.)has been met according to the results published in the JAMA Neurology.
    • 19 Sep 2022 Results assessing the efficacy and safety of Rituximab for New-Onset Generalized Myasthenia Gravis published in the JAMA Neurology.
    • 02 Dec 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top